PMID- 15470906
OWN - NLM
STAT- MEDLINE
DCOM- 20041109
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 27
IP  - 7 Suppl 4
DP  - 2004 Jul
TI  - What are the effects of peroxisome proliferator-activated receptor agonists on 
      adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin 
      resistance?
PG  - IV11-6
AB  - Patients with type 2 diabetes are at high risk of cardiovascular disease. In 
      addition to treating hyperglycemia, the thiazolidinedione (TZD) class of 
      antidiabetic agents may also benefit the cardiovascular complications associated 
      with the disease. The two available TZDs, pioglitazone and rosiglitazone, are 
      peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists that 
      influence gene expression of key proteins involved in regulating glucose and 
      lipid metabolism. Tumor necrosis factor-alpha (TNF-alpha) and adiponectin are 
      believed to be important in the development of insulin resistance and 
      atherosclerosis. Understanding the role of these cytokines in the inflammatory 
      processes that trigger plaque development might lead to identification of other 
      potential mechanisms that could be exploited to enhance future treatments for 
      patients with diabetes and atherosclerosis.
FAU - Boyle, Patrick J
AU  - Boyle PJ
AD  - University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA. 
      pboyle@salud.unm.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Adiponectin)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Proteins)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adiponectin
MH  - Animals
MH  - Apolipoproteins E/deficiency/physiology
MH  - Arteriosclerosis/physiopathology
MH  - Cardiovascular Diseases/physiopathology
MH  - Cytokines/drug effects/immunology
MH  - Diabetes Mellitus, Type 2/physiopathology
MH  - Glucose/metabolism
MH  - Humans
MH  - Insulin Resistance/*immunology/physiology
MH  - *Intercellular Signaling Peptides and Proteins
MH  - Lipid Metabolism
MH  - Proteins/*drug effects/immunology
MH  - Receptors, Cytoplasmic and Nuclear/agonists
MH  - Thiazolidinediones/agonists/*pharmacology
MH  - Transcription Factors/agonists/*pharmacology
MH  - Tumor Necrosis Factor-alpha/*drug effects/immunology
PMC - PMC6654333
EDAT- 2004/10/09 09:00
MHDA- 2004/11/13 09:00
PMCR- 2007/07/05
CRDT- 2004/10/09 09:00
PHST- 2004/10/09 09:00 [pubmed]
PHST- 2004/11/13 09:00 [medline]
PHST- 2004/10/09 09:00 [entrez]
PHST- 2007/07/05 00:00 [pmc-release]
AID - CLC4960271604 [pii]
AID - 10.1002/clc.4960271604 [doi]
PST - ppublish
SO  - Clin Cardiol. 2004 Jul;27(7 Suppl 4):IV11-6. doi: 10.1002/clc.4960271604.